脑出血后恢复口服抗凝治疗与功能结局的荟萃分析
该研究汇总三项队列共1012例口服抗凝相关脑出血幸存者(非脑叶633例、脑叶379例),采用倾向评分匹配与Cox回归分析发病1年内恢复口服抗凝治疗与死亡、功能结局及卒中发生的关系。结果显示,无论血肿位于脑叶还是非脑叶,恢复抗凝均与死亡风险降低、功能结局改善及全因卒中发生率降低相关。作者据此建议开展随机对照试验验证其风险与获益。
要点
- 非脑叶脑出血后恢复口服抗凝与死亡风险降低相关(HR=0.25,95%CI 0.14-0.44)。
- 脑叶脑出血后恢复抗凝同样与死亡风险降低相关(HR=0.29,95%CI 0.17-0.45)。
- 两类部位恢复抗凝均与功能结局改善及全因卒中发生率降低相关,支持开展随机试验。
核心结论
- 口服抗凝相关脑出血幸存者恢复口服抗凝治疗与死亡风险降低、功能结局改善及全因卒中发生率降低相关,且该关联不受血肿部位(脑叶与非脑叶)影响。
- 上述结果为观察性关联证据,作者认为支持开展随机对照试验以明确脑出血后恢复口服抗凝治疗的风险与获益。
研究设计与样本
- 研究为个体患者数据的荟萃分析,整合三项研究:多中心RETRACE研究(n=542)、美国单中心脑出血研究(n=261)及脑出血种族/民族差异研究(n=209)。
- 共纳入1012例口服抗凝相关脑出血幸存者,其中非脑叶633例、脑叶379例;采用倾向评分匹配与Cox回归模型,分别分析非脑叶与脑叶病例。
- 评估指标为脑出血后1年内恢复口服抗凝治疗与死亡、良好功能结局(改良Rankin量表=0-3)及卒中发生率的关联。
主要发现
- 非脑叶脑出血幸存者中178/633(28%)恢复口服抗凝治疗,脑叶脑出血幸存者中86/379(23%)恢复治疗。
- 非脑叶脑出血后恢复抗凝与死亡风险降低相关(HR=0.25,95%CI=0.14-0.44,p<0.0001),并与功能结局改善相关(HR=4.22,95%CI=2.57-6.94,p<0.0001)。
- 脑叶脑出血后恢复抗凝与死亡风险降低相关(HR=0.29,95%CI=0.17-0.45,p<0.0001),并与功能结局改善相关(HR=4.08,95%CI=2.48-6.72,p<0.0001)。
- 恢复抗凝与脑叶及非脑叶脑出血的全因卒中发生率降低均相关(均p<0.01)。
临床怎么用
- 对口服抗凝相关脑出血幸存者,恢复抗凝的决策需权衡缺血性卒中与再出血风险,该研究提示恢复抗凝可能与更好结局相关,但证据来自观察性数据,不能直接确立因果关系。
- 鉴于脑叶出血常与淀粉样血管病相关,临床决策应结合血肿部位个体化评估,并可与患者及家属充分沟通后决定是否恢复抗凝。
局限性
- 研究为观察性个体数据荟萃分析,恢复抗凝组与未恢复组间可能存在未测量的混杂因素,无法确立因果关系。
- 作者明确指出需开展随机对照试验以进一步验证脑出血后恢复口服抗凝治疗的风险与获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Oral anticoagulation treatment (OAT) resumption is a therapeutic dilemma in intracerebral hemorrhage (ICH) care, particularly for lobar hemorrhages related to amyloid angiopathy. We sought to determine whether OAT resumption after ICH is associated with long-term outcome, accounting for ICH location (ie, lobar vs nonlobar). METHODS: We meta-analyzed individual patient data from: (1) the multicenter RETRACE study (n = 542), (2) a U.S.-based single-center ICH study (n = 261), and (3) the Ethnic/Racial Variations of Intracerebral Hemorrhage study (n = 209). We determined whether, within 1 year from ICH, OAT resumption was associated with: (1) mortality, (2) favorable functional outcome (modified Rankin Scale = 0-3), and (3) stroke incidence. We separately analyzed nonlobar and lobar ICH cases using propensity score matching and Cox regression models. RESULTS: We included 1,012 OAT-related ICH survivors (633 nonlobar and 379 lobar). Among nonlobar ICH survivors, 178/633 (28%) resumed OAT, whereas 86/379 (23%) lobar ICH survivors did. In multivariate analyses, OAT resumption after nonlobar ICH was associated with decreased mortality (hazard ratio [HR] = 0.25, 95% confidence interval [CI] = 0.14-0.44, p < 0.0001) and improved functional outcome (HR = 4.22, 95% CI = 2.57-6.94, p < 0.0001). OAT resumption after lobar ICH was also associated with decreased mortality (HR = 0.29, 95% CI = 0.17-0.45, p < 0.0001) and favorable functional outcome (HR = 4.08, 95% CI = 2.48-6.72, p < 0.0001). Furthermore, OAT resumption was associated with decreased all-cause stroke incidence in both lobar and nonlobar ICH (both p < 0.01). INTERPRETATION: These results suggest novel evidence of an association between OAT resumption and outcome following ICH, regardless of hematoma location. These findings support conducting randomized trials to explore risks and benefits of OAT resumption after ICH. Ann Neurol 2017;82:755-765.
引用
- Biffi A, Kuramatsu JB, Leasure A, et al. Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol. 2017. PMID: 29028130. doi:10.1002/ana.25079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。